# QDENGA (TAK-003)

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/qdenga-tak-003
Canonical HTML page: https://getyourbrief.com/entity/qdenga-tak-003

## Recent coverage (2 stories, network-wide)

### India OKs First Dengue Shot: QDENGA Targets 33% of Global Burden
2026-07-25 04:23:24 · Sector: health · Sentiment: Strongly positive · Impact: 7/10 · Sources: 2

DCGI's authorization of QDENGA brings India its first dengue vaccine, a no‑screening option that could reshape public health strategy. With the country bearing a third of the world's dengue cases, the vaccine promises to reduce hospitalizations and ease endemic pressure on healthcare systems.
Full story: https://gethealthbrief.com/story/india-qdenga-dengue-vaccine-approval-health-impact

### Takeda's QDENGA Cleared in India: No‑Screen Shot Targets 33% Dengue Burden
2026-07-25 04:23:17 · Sector: bio · Sentiment: Strongly positive · Impact: 7/10 · Sources: 2

Takeda's QDENGA gains DCGI approval in India, unlocking a market that bears one‑third of global dengue cases. The vaccine's differentiation—no pre‑screening required and broad 4–60 age label—positions it strongly against legacy products like Sanofi's Dengvaxia.
Full story: https://getbiobrief.com/story/takeda-qdenga-dcgi-approval-biotech

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.